Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42585   clinical trials with a EudraCT protocol, of which   7011   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-000333-39
    Sponsor's Protocol Code Number:Darvadstrocel-3003
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-05-24
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-000333-39
    A.3Full title of the trial
    A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
    Follow-up di uno studio di Fase 3 volto a valutare la sicurezza e l’efficacia a lungo termine di darvadstrocel nel trattamento della fistola perianale complessa in soggetti con malattia di Crohn che hanno partecipato allo Studio ADMIRE II
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
    Studio di follow-up a lungo termine con darvadstrocel nel trattamento della fistola perianale complessa
    A.3.2Name or abbreviated title of the trial where available
    Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
    Studio di follow-up a lungo termine con darvadstrocel nel trattamento della fistola perianale comple
    A.4.1Sponsor's protocol code numberDarvadstrocel-3003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMILLENNIUM PHARMACEUTICALS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMillennium Pharmaceuticals, Inc (MPI)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMillennium Pharmaceuticals, Inc (MPI)
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressC/ Marconi 1. Parque Tecnológico de Madrid
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28760
    B.5.3.4CountrySpain
    B.5.4Telephone number0034918049264
    B.5.5Fax number0034918049263
    B.5.6E-mailinmaculada.gilaberte@takeda.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Alofisel
    D.2.1.1.2Name of the Marketing Authorisation holderTakeda Pharma A/S, Dybendal Alle 10, 2630 Taastrup, Denmark
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/667
    D.3 Description of the IMP
    D.3.1Product nameCx601
    D.3.2Product code [Cx601]
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntralesional use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDarvadstrocel
    D.3.9.2Current sponsor codeAllogenic eASCs
    D.3.9.3Other descriptive nameExpanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs)
    D.3.9.4EV Substance CodeSUB190583
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product Yes
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntralesional use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Perianal fistulising Crohn´s disease
    Fistole perianali nella malattia di Crohn
    E.1.1.1Medical condition in easily understood language
    Treatment for perianal fistulising Crohn´s disease
    Trattamento delle fistole perianali nella malattia di Crohn
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10002156
    E.1.2Term Anal fistula
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the long-term safety of a single dose of darvadstrocel in subjects with CD and complex perianal fistula by evaluation of AEs, serious adverse events (SAEs), and adverse events of special interest (AESIs).
    Valutare la sicurezza a lungo termine di una dose singola di darvadstrocel in soggetti con MC e fistola perianale complessa mediante valutazione degli EA, SAE e AESI.
    E.2.2Secondary objectives of the trial
    To evaluate the long-term efficacy of a single dose of darvadstrocel for the treatment of complex perianal fistula(s) in subjects with CD.
    Valutare l’efficacia a lungo termine di una dose singola di darvadstrocel per il trattamento di fistole perianali complesse in soggetti con MC.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subject eligibility is determined according to the following criteria before entry into the study:
    1. In the opinion of the investigator, the subject is capable of understanding and complying withprotocol requirements.
    2. The subject or, when applicable, the subject's legally acceptable representative signs and dates a written ICF and any required privacy authorization before the initiation of any study procedures.
    3. The subject has participated in and completed the ADMIRE-CD II study (ie, did not discontinue).
    L’idoneità del soggetto è determinata in base ai seguenti criteri prima dell’ingresso nello studio:
    1. In base all’opinione dello sperimentatore, il soggetto è in grado di comprendere e attenersi ai requisiti del protocollo.
    2. Il soggetto o, se del caso, il rappresentante legale autorizzato del soggetto firmerà e daterà un ICF scritto, e un’eventuale autorizzazione alla privacy richiesta, prima dell’inizio di qualsiasi procedura dello studio.
    3. Il soggetto ha partecipato a, e completato, lo studio ADMIRE-CD II (ovvero, non si è/è stato ritirato).
    E.4Principal exclusion criteria
    Subjects will not be eligible for inclusion in the study if:
    1. It has been more than 3 months since the subject completed the ADMIRE-CD II study.
    2. Subjects are currently receiving, have received any investigational drug in the last 3 months before the inclusion in the study, or are planning to receive any investigational drug during the duration of this
    LTE study, except for prior participation in the ADMIRE-CD II study.
    I soggetti non risulteranno idonei per essere inclusi nello studio se:
    1. Sono passati più di 3 mesi da quando il soggetto ha completato lo studio ADMIRE-CD II.
    2. I soggetti sono attualmente in trattamento o sono stati in trattamento con un qualsiasi farmaco sperimentale negli ultimi 3 mesi prima dell’inclusione nello studio, o prevedono di essere trattati con un qualsiasi farmaco sperimentale durante il periodo di questo studio LTE, fatta eccezione per la precedente partecipazione allo studio ADMIRE-CD II.
    E.5 End points
    E.5.1Primary end point(s)
    • AEs.
    • SAEs.
    • Specific AESIs:
    – Immunogenicity/alloimmune reactions.
    – Tumorgenicity.
    – Ectopic tissue formation.
    • EA.
    • SAE.
    • AESI specifici:
    - Immunogenicità/reazioni alloimmuni.
    - Tumorigenicità.
    - Formazione di tessuto ectopico.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Examinations/assessments at week 0, 52, 104.
    Telephone calls every 3 months.
    Esaminazioni/valutazioni alla settimana 0, 52, 104.
    Contatti telefonici ogni 3 mesi.
    E.5.2Secondary end point(s)
    Proportion of subjects who achieve clinical remission at Week 104 and Week 156 after IMP administration.
    – Clinical remission is defined as closure of all treated external fistula openings that were draining at baseline despite gentle finger compression.
    - Proportion of subjects who achieve clinical response at Week 104 and Week 156 after IMP administration.
    – Clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression.
    Proportion of subjects with a relapse where a relapse is defined as:
    – Reopening of any of the treated fistula(s) external openings with active drainage as clinically assessed in subjects who were in clinical remission at Week 52, or
    – The development of a perianal fluid collection >2 cm of the treated perianal fistulas confirmed by centrally read magnetic resonance imaging (MRI) assessment.
    - Proportion of subjects who achieve combined remission at Week 156 after IMP administration.
    –- Combined remission of complex perianal fistula(s), defined as the clinical assessment of closure of all treated external openings that were draining at baseline (ie, screening visit), despite gentle finger compression, and
    –- Absence of collection(s) >2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by centrally read blinded MRI assessment.
    - Proportion of subjects with new anal abscess in treated fistula.
    - Change from baseline to Week 104 and Week 156 after IMP administration in in scores of discharge and pain items of Perianal Disease Activity Index (PDAI) score.
    Percentuale di soggetti che raggiungono la remissione clinica alla Settimana 104 e alla Settimana 156 dopo la somministrazione dell’IMP.
    – La remissione clinica è definita come la chiusura di tutte le aperture esterne trattate della fistola che erano drenanti al basale nonostante una lieve pressione del dito.
    - Percentuale di soggetti che raggiungono la risposta clinica alla Settimana 104 e alla Settimana 156 dopo la somministrazione dell’IMP.
    – La risposta clinica è definita come la chiusura di almeno il 50% di tutte le aperture esterne trattate della fistola che erano drenanti al basale nonostante una lieve pressione del dito.
    Percentuale di soggetti con una recidiva, ove per recidiva si intende:
    – Riapertura delle aperture esterne della/e fistola/e trattata/e con drenaggio attivo, secondo la valutazione clinica in soggetti in remissione clinica alla Settimana 52, o
    – Sviluppo di una raccolta di ascesso perianale > 2 cm delle fistole perianali trattate, confermato da valutazione RM letta a livello centrale.
    - Percentuale di soggetti che raggiungono la remissione combinata alla Settimana 156 dopo la somministrazione dell’IMP.
    – Remissione combinata di fistola/e perianale/i complessa/e, definita come la valutazione clinica della chiusura di tutte le aperture esterne trattate che erano drenanti al basale (ovvero, alla visita di screening), nonostante una lieve pressione del dito, e
    – Assenza di raccolta/e > 2 cm (in almeno 2 dimensioni) della/e fistola/e perianale/i trattata/e, confermata da valutazione RM in cieco letta a livello centrale.
    - Percentuale di soggetti con nuovo ascesso anale nella fistola trattata.
    - Variazione dal basale alla Settimana 104 e alla Settimana 156, dopo la somministrazione dell’IMP, dei punteggi delle voci “ascesso” e “dolore” sull’Indice di attività della malattia perianale (PDAI).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Examinations/assessments at week 0, 52, 104.
    Telephone calls every 3 months.
    Esaminazioni/valutazioni alla settimana 0, 52, 104.
    Contatti telefonici ogni 3 mesi.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    Czechia
    France
    Germany
    Hungary
    Israel
    Italy
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 124
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 26
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 45
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No plans are foreseen.
    Non sono previsti programmi.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-12-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-10-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA